Genflow Biosciences PLC (LSE:GENF) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new ordinary shares (and/or warrants) Announced: private placement Use of proceeds: Moving MASH program to IND-enabling stage, animal health dog trial payment and licensing, glaucoma proof of concept studies, and EU and US patent work | Feb 11, 2026 | |
| Private placement of new ordinary shares with warrants Cancelled: £340,000 · £0.85 a share · Warrants at £1.2 for 24 months Buyers: Eric Leire (40,000,000 new ordinary shares at 0.85 pence, to be directed to an institution for sale to a purchaser) Insiders: Subscription by CEO and director Eric Leire, who will direct the shares to an institution for immediate sale to a purchaser Use of proceeds: Continue the dog study while awaiting the Wallonia region grant; working capital | Oct 9, 2025 | US$456,978 |
| Private placement of new ordinary shares with warrants Closed: £440,000 raised · GBX 1.1 a share · Warrants at GBX 1.2 for 24 months Buyers: Eric Leire (4,545,454 New Ordinary Shares); consortium of existing shareholders (35,454,546 New Ordinary Shares) Insiders: CEO and director Eric Leire subscribed for the 40,000,000 shares, directing 35,454,546 to existing shareholders and keeping 4,545,454 | Oct 9, 2025 | US$586,174 |
| Private placement of new ordinary shares with warrants Closed: £500,000 raised · GBX 0.8 a share · Warrants at GBX 1.5 for 36 months Buyers: Eric Leire (subscription for 62,500,000 New Ordinary Shares, to be directed to an institution and sold to a purchaser) Insiders: Subscription by CEO and director Eric Leire, who directs the shares to an institution that sells them to a purchaser at the same price Use of proceeds: Advance a proof-of-concept trial of its therapeutic candidate in aged dogs | May 9, 2025 | US$665,147 |